Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
Public ClinicalTrials.gov record NCT00677716. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
Study identification
- NCT ID
- NCT00677716
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Aug 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- Apr 23, 2014
2007 – 2011
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| University of Pennsylvania, Department of Neurosurgery | Philadelphia | Pennsylvania | 19104 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
Recently updated Glioblastoma Multiforme trials
Other public records listing Glioblastoma Multiforme. Sorted by last update posted; newest first. Not a recommendation.
- NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Active, not recruiting
- NCT04900792: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Active, not recruiting
- NCT05864976: Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning Recruiting
- NCT02177578: Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme Active, not recruiting
- NCT05120284: Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) Active, not recruiting
- NCT06011109: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00677716, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00677716 live on ClinicalTrials.gov.